LitAlert ~~ GeneLit.com

    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • Pre-activation of autophagy impacts response to olaparib in prostate cancer cells.
    • Cahuzac M, Langlois P, Péant B, Fleury H, Mes-Masson AM, Saad F.
    • Commun Biol. 2022 Mar 22;5(1):251. doi: 10.1038/s42003-022-03210-5.
    • Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    • Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S.
    • Int J Gynecol Cancer. 2022 Mar 22:ijgc-2022-003435. doi: 10.1136/ijgc-2022-003435. Epub ahead of print.
    • Study protocol

    Clinical Trials: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) (ClinicalTrials.gov)